Premier Alternatives

Huadao Biopharma

Shanghai, China · Founded 2017 · Privately Held (backing)

Developer of cell immunotherapy technology designed for oncology. Huadao Biopharma is based in Shanghai, China and was founded in 2017. Its last reported valuation was $79.9 million in Jul 2019. It has raised $58.8 million.

Last reported valuation
$79.9M
Oct 2026
Priced at
—
Total raised
$58.8M
Last round
—

Huadao Biopharma key facts

as of Oct 2026
  • Developer of cell immunotherapy technology designed for oncology.
  • Huadao Biopharma is valued at approximately $79.9M as of Oct 2026 (last reported valuation).
  • It has raised $58.8M; the latest was Later Stage VC ($14.0M) in Oct 2025.
  • Notable investors include Hankang Capital, Shanghai Songjiang State-owned Assets Investment, Jiaxing Jiarui Investment Management, Zhejiang Haiyue Asset Management, Chongqing Technology Venture Capital — 20 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$79.9M

Huadao Biopharma's last reported valuation, Jul 2019. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Huadao Biopharma with a free account
  • ·The complete investor list: 20 names
  • ·Watch Huadao Biopharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Huadao Biopharma funding rounds

No rounds on record

No funding rounds for Huadao Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Huadao Biopharma valuation

Huadao Biopharma's last reported valuation was $79.9 million in Jul 2019. No priced round, secondary trade or fund mark has surfaced since.

Huadao Biopharma investors

20 investors are on record for Huadao Biopharma, including Hankang Capital, Shanghai Songjiang State-owned Assets Investment, Jiaxing Jiarui Investment Management and Zhejiang Haiyue Asset Management.

About Huadao Biopharma

Developer of cell immunotherapy technology designed for oncology. The company develops CAR-T (chimeric antigen receptor-T) cell technologies including bacteria fermentation engineering, virus purification technique, T cell acquisition, and cell harvesting, providing healthcare practitioners with research resources and expertise to treat acute lymphoblastic leukemia and related diseases.

Sector
Healthcare
HQ
Shanghai, China
Founded
2017
Employees
83
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.